Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BGY-1601-VT in Acute Vaginal Infection
2023-508958-26-00Phase 2Completed
- Sponsor
- Nexbiome Therapeutics
- Start
- Jun 2024
- Modality
- Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in bacterial vaginosis (BV), vulvovaginal candidiasis (VVC) and vaginitis comparing BGY-1601-VT vaginal tablet with Placebo vaginal tablet (2 arms). Primary endpoint: Percentage of responders at V2. Started Jun 2024; status: completed.
02
Drugs
BGY-1601-VT
03
Conditions
bacterial vaginosis (BV)vulvovaginal candidiasis (VVC)vaginitis
Beyond the preview
Go deeper on 2023-508958-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508958-26-00.